Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

被引：62

作者：

Sockel, Katja

Wermke, Martin

Radke, Joergen

Kiani, Alexander ^{[2
]}

Schaich, Markus

Bornhaeuser, Martin

Ehninger, Gerhard

Thiede, Christian

Platzbecker, Uwe ^{[1
]}

机构：

[1] Univ Klinikum Carl Gustav Carus, Med Klin 1, Med Klin & Poliklin 1, D-01307 Dresden, Germany

[2] Klinikum Bayreuth, Bayreuth, Germany

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2011年 / 96卷 / 10期

关键词：

AML; nucleophosmin; NPM1; MRD; azacitidine;

D O I：

10.3324/haematol.2011.044388

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1568 / 1570

页数：4

共 10 条

[1] Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation [J].

Bacher, Ulrike ;

Badbaran, Anita ;

Fehse, Boris ;

Zabelina, Tatjana ;

Zander, Axel Rolf ;

Kroeger, Nicolaus .

EXPERIMENTAL HEMATOLOGY, 2009, 37 (01) :135-142

[2] Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome [J].

de Lima, Marcos ;

Giralt, Sergio ;

Thall, Peter F. ;

Silva, Leandro de Padua ;

Jones, Roy B. ;

Komanduri, Krishna ;

Braun, Thomas M. ;

Nguyen, Hoang Q. ;

Champlin, Richard ;

Garcia-Manero, Guillermo .

CANCER, 2010, 116 (23) :5420-5431

[3] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[4] Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia [J].

Goodyear, Oliver ;

Agathanggelou, Angelo ;

Novitzky-Basso, Igor ;

Siddique, Shamyla ;

McSkeane, Tina ;

Ryan, Gordon ;

Vyas, Paresh ;

Cavenagh, Jamie ;

Stankovic, Tanja ;

Moss, Paul ;

Craddock, Charles .

BLOOD, 2010, 116 (11) :1908-1918

[5] Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations [J].

Gorello, P. ;

Cazzaniga, G. ;

Alberti, F. ;

Dell'Oro, M. G. ;

Gottardi, E. ;

Specchia, G. ;

Roti, G. ;

Rosati, R. ;

Martelli, M. F. ;

Diverio, D. ;

Lo Coco, F. ;

Biondi, A. ;

Saglio, G. ;

Mecucci, C. ;

Falini, B. .

LEUKEMIA, 2006, 20 (06) :1103-1108

[6] Assessment of minimal residual disease in acute myeloid leukemia [J].

Grimwade, David ;

Vyas, Paresh ;

Freeman, Sylvie .

CURRENT OPINION IN ONCOLOGY, 2010, 22 (06) :656-663

[7] Towards individualized follow-up in adult acute myeloid leukemia in remission [J].

Hokland, Peter ;

Ommen, Hans Beier .

BLOOD, 2011, 117 (09) :2577-2584

[8] Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML [J].

Schnittger, Susanne ;

Kern, Wolfgang ;

Tschulik, Claudia ;

Weiss, Tamara ;

Dicker, Frank ;

Falini, Brunangelo ;

Haferlach, Claudia ;

Haferlach, Torsten .

BLOOD, 2009, 114 (11) :2220-2231

[9]

Shayegi N, 2011, BONE MARROW TRANSPLA

[10] Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine [J].

Wermke, M. ;

Thiede, C. ;

Kiani, A. ;

Ehninger, G. ;

Bornhaeuser, M. ;

Platzbecker, U. .

LEUKEMIA, 2010, 24 (01) :236-237

← 1 →